This Article  • Abstract  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (376)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Asthma  • Evidence-Based Medicine  • Allergy  • Alert me on articles by topic  Social Bookmarking   What's this?

A Systematic Review and Meta-analysis

Brian J. Lipworth, MD, FRCPE

Arch Intern Med. 1999;159:941-955.

ABSTRACT
Objective  To appraise the data on systemic adverse effects of inhaled corticosteroids.

Methods  A computerized database search from January 1, 1966, through July 31, 1998, using MEDLINE, EMBASE, and BIDS and using appropriate indexed terms. Reports dealing with the systemic effects of inhaled corticosteroids on adrenal gland, growth, bone, skin, and eye, and reports on pharmacology and pharmacokinetics were reviewed where appropriate. Studies were included that contained evaluable data on systemic effects in healthy volunteers as well as in asthmatic children and adults. A statistical meta-analysis using regression was performed for parameters of adrenal suppression in 27 studies.

Results  Marked adrenal suppression occurs with high doses of inhaled corticosteroid above 1.5 mg/d (0.75 mg/d for fluticasone propionate), although there is a considerable degree of interindividual susceptibility. Meta-analysis showed significantly greater potency for dose-related adrenal suppression with fluticasone compared with beclomethasone dipropionate, budesonide, or triamcinolone acetonide, whereas prednisolone and fluticasone propionate were approximately equivalent on a 10:1-mg basis. Inhaled corticosteroids in doses above 1.5 mg/d (0.75 mg/d for fluticasone propionate) may be associated with a significant reduction in bone density, although the risk for osteoporosis may be obviated by postmenopausal estrogen replacement therapy. Although medium-term growth studies showed suppressive effects with 400-µg/d beclomethasone dipropionate, there was no evidence to support any significant effects on final adult height. Long-term, high-dose inhaled corticosteroid exposure increases the risk for posterior subcapsular cataracts, and, to a much lesser degree, the risk for ocular hypertension and glaucoma. Skin bruising is most likely to occur with high-dose exposure, which correlates with the degree of adrenal suppression.

Conclusions  All inhaled corticosteroids exhibit dose-related systemic adverse effects, although these are less than with a comparable dose of oral corticosteroids. Meta-analysis shows that fluticasone propionate exhibits greater dose-related systemic bioactivity compared with other available inhaled corticosteroids, particularly at doses above 0.8 mg/d. The long-term systemic burden will be minimized by always trying to achieve the lowest possible maintenance dose that is associated with optimal asthmatic control and quality of life.

INTRODUCTION

Jump to Section  • Top  • Introduction  • Materials and methods  • Results  • Comment  • Author information  • References

THE LAST decade has led to a greater understanding of the mechanisms causing asthma and particularly the underlying role of the inflammatory process in this condition. Corticosteroids are generally accepted to be the first-line choice of anti-inflammatory therapy for the treatment of asthma.^1-2 The delivery of topically active corticosteroids directly to the airways by inhalation has revolutionized the anti-inflammatory treatment of asthma. As a consequence, it is now relatively uncommon to see the unpleasant systemic adverse effects that are associated with oral corticosteroid maintenance therapy.

Present asthma management guidelines emphasize the importance of early intervention with inhaled corticosteroids as first-line anti-inflammatory therapy.^1-2 There has been a trend toward the use of higher doses, which seems contrary to most of the available evidence of the dose-response relationships for efficacy of inhaled corticosteroids in asthma.³ Against this background, there has been increasing awareness that inhaled corticosteroids are associated with dose-related systemic adverse effects. This in turn has resulted in debate regarding the relative risks and benefits of newer vs older inhaled corticosteroids. At the same time, there has been increasing awareness that adding long-acting ₂-agonists, theophyllines, or antileukotrienes may be an option to increasing the dose of inhaled corticosteroid, to achieve optimal long-term control.

The purpose of this article is to provide an objective and systematic review of the systemic adverse effects of inhaled corticosteroid therapy and the clinical relevance of inhaled corticosteroids in the treatment of asthmatic patients. In particular, the article will focus on the effects on adrenal gland, growth, bone, eye, and skin.

MATERIALS AND METHODS

Jump to Section  • Top  • Introduction  • Materials and methods  • Results  • Comment  • Author information  • References

The literature was searched for 30 key terms from January 1, 1966, through July 31, 1998, using the the databases of MEDLINE (National Library of Medicine), EMBASE (Excerpta Medica), and BIDS (Institute for Scientific Information). In addition, the bibliographies of eligible articles and reviews were used along with scientific session abstracts in key respiratory- and allergy-based journals. Eligible studies for review provided sufficient information on patient demographics, study design, randomization and control procedures, route of drug administration, measurement of end points, and data analysis.

The main results of this review were qualitative, as it was not possible to perform an overall statistical meta-analysis due to the wide variation in selected end points for a given tissue-specific effect. However, where appropriate, a given end point was analyzed to produce a comparable response across different studies. This was only possible for end points of adrenal suppression, where there were sufficient evaluable data, namely, for effects on 8 AM plasma or serum cortisol levels and on urinary cortisol (or cortisol-creatinine) excretion (24-hour or overnight). There were 21 eligible studies for urinary cortisol levels and 13 eligible studies for 8 AM cortisol levels, constituting a total of 27 different studies for both end points. For these data, model fitting was applied using multiple regression analysis of slopes to ascertain whether there were significant differences in slope gradients between drugs. The different studies were weighted according to their sample size when performing the regression analysis. Differences between slope gradients were also calculated using 95% confidence intervals (CIs).

The format for this article is first to provide a general overview of factors that determine the systemic bioactivity profile of inhaled corticosteroids, followed by a detailed appraisal of tissue-specific adverse effects, including the results of the meta-analysis for adrenal suppression. It is not within the scope of this article to discuss the antiasthmatic efficacy of inhaled corticosteroids in any detail, as this has been reviewed elsewhere with respect to dose-response relationships and risk-benefit ratio.

PHARMACOLOGIC AND PHARMACOKINETIC DETERMINANTS

Lipophilic substitutions of the basic glucocorticosteroid nucleus result in compounds that exhibit a high level of receptor potency and affinity, a high degree of local tissue uptake and retention with topical application, and a high degree of first-pass biotransformation in the liver. Corticosteroids administered by inhalation exhibit a high degree of topical potency at the glucocorticoid receptor, and so delivery of low doses may achieve a high local concentration within the airway. The degree of topical potency is assessed conventionally using the skin vasoconstrictor assay. Using this method, an approximate rank-order potency ratio can be calculated for the different inhaled corticosteroids in the following order (from greatest to least potency): fluticasone propionate, budesonide, beclomethasone dipropionate, triamcinolone acetonide, and flunisolide acetate.^4-7 However, it is probably not possible to extrapolate comparative topical potency data in skin directly to topical antiasthmatic effects in airways or to effects on glucocorticoid receptors in systemic tissues.

The degree of topical activity is also related to the affinity for glucocorticoid receptor binding.⁸ Indeed, the rank order for relative receptor affinity is similar to that for potency from the vasoconstrictor assay.^9-10 The residency time for the receptor-drug complex is also related to the binding affinity, and in this respect the residency half-time is longest for fluticasone.¹⁰ Although a higher level of binding affinity and a longer receptor residency time may result in greater topical efficacy, the same is also likely to be the case in terms of a greater degree of activity at systemic glucocorticoid receptors. In other words, enhanced potency and affinity may cause a commensurate increase in systemic and airway bioactivity profiles. The ratio of airway to systemic activity will also depend on the relative dose-response relationships for airway efficacy and systemic adverse effects. Thus, increasing the dose of inhaled corticosteroid on the flat part of the efficacy curve will confer little further benefit, but at the same time may coincide with the steep part of the systemic curve, resulting in a worse therapeutic index.³

Evidence also suggests that the degree of lipophilicity will determine the dwell time at the local tissue site after topical administration.¹¹ A high degree of lipophilicity will also result in a larger volume of distribution due to more extensive binding within systemic tissues.¹² In this respect, fluticasone has the highest level of lipophilicity among the inhaled corticosteroids,⁹ which may in part explain the greater systemic activity of this compound as a consequence of more prolonged systemic tissue retention. Thus, enhanced lipophilicity may represent a 2-edged sword in terms of greater airway and systemic retention.

The specific purpose of inhaled corticosteroid therapy is to target drug delivery directly to the site of airway inflammation. With pressurized metered-dose inhaler devices, most of the dose delivered to the patient is deposited in the oropharynx (>60%), with a much smaller proportion reaching the lungs (<20%). Although there is a small degree of direct absorption from the buccal cavity, most of the oropharyngeal dose is swallowed and subsequently absorbed from the gastrointestinal tract.¹³ For all of the inhaled corticosteroids except beclomethasone, there is no first-pass transformation in the lung. Thus, most of the respirable dose delivered to the lung will be bioavailable in the systemic circulation as unchanged active drug. For the swallowed moiety, absorption occurs from the gastrointestinal tract via the portal circulation to the liver, where there is a varying degree of first-pass metabolism to inactive metabolites, ie, 70% for beclomethasone, 90% for budesonide and triamcinolone, and 99% for fluticasone.^14-17 The situation for beclomethasone is somewhat different in that there is partial transformation to metabolites that are active (17-beclomethasone monopropionate) and inactive (21-beclomethasone monopropionate).¹⁸ It is evident that the lung component of absorption is the larger determinant of the overall systemic bioavailability for inhaled corticosteroids that exhibit a high degree of first-pass inactivation, such as fluticasone, budesonide, and triamcinolone.

It is also pertinent to consider the pharmacokinetic profile and in particular the elimination half-life, as this will determine the degree of accumulation after steady state dosing. Fluticasone propionate has an elimination half-life of 14.4 hours, which is considerably longer than that of other corticosteroids, including budesonide (2.3 hours), triamcinolone (3.6 hours), flunisolide (1.6 hours) and beclomethasone monopropionate (6.5 hours).^{12, 14, 17, 19-21} Thus, with a 12-hour dosing interval for fluticasone, the average plasma concentration is approximately 1.7 times higher after repeated dosing compared with single dosing.¹² This degree of steady state accumulation with fluticasone is in keeping with a 2-fold increase in adrenal suppression between single- and repeated-dose administration.^22-23 In contrast, the much shorter elimination half-life of budesonide results in no significant steady state accumulation, and therefore no significant increase in adrenal suppression between single and repeated dosing.²³ This emphasizes the need to perform comparative studies at the steady state, as effects with single dosing will be less for a drug with a long elimination half-life.

CLINICAL STUDY DESIGN

When comparing different drugs, it is important to consider their respective delivery devices, as the respirable fraction will determine clinical efficacy and lung absorption. The effects of mouth rinsing or using a spacer will be determined by the degree of first-pass inactivation for the swallowed fraction as well as the increase in respirable dose with a spacer.^24-27 In comparing different drugs, it is also important to evaluate a full dose-response curve for a range of usually recommended therapeutic doses. The relative systemic potency ratio can be calculated by comparing 2 drugs on the steep part of their respective dose-response curves using a sufficiently sensitive end point.^28-31 It is not valid to make a relative assessment of 2 drugs using arbitrary doses given on the basis of a putative topical potency ratio, eg, comparing beclomethasone with half the dose of fluticasone.^32-35 From this type of study, it is not possible to assess whether the observed effect of each drug corresponds to the steep part of its respective dose-response curve. Ideally, the relative potency ratio would be calculated for efficacy and systemic activity in the same study, to assess a comparative therapeutic index for both drugs. In practice, this is extremely difficult to achieve, because the steep part of the dose-response curve for clinical efficacy does not usually coincide with the steep part of the curve for systemic activity.³ Thus, it may not be possible to calculate a true systemic potency ratio for therapeutically equivalent doses of 2 different drugs.

The type of subject used for evaluation may also be an important factor. A reduction in peripheral airway caliber in asthmatic patients may significantly reduce the degree of lung absorption and hence influence the systemic bioactivity.¹³ Thus, for a given drug, the absolute magnitude of systemic effect may be overestimated if this is evaluated in healthy volunteers who have normal airway caliber.³⁶ Likewise, it may not be possible to extrapolate effects in patients with mild asthma to what happens in patients with more severe asthma due to differences in lung absorption for a given dose. However, when comparing 2 drugs, the relative difference in systemic activity will probably be the same in healthy subjects as in asthmatics, providing that the identical end point is used. Another important factor when studying patients is that there may be effects of previous corticosteroid exposure, eg, as in considering the legacy of previous prednisone treatment.³⁷

The sensitivity of the measured end points for the study will also have a major bearing on the results. For example, in studies looking at adrenal suppression, the timing of spot measurements of early morning cortisol concentration is critical, in that peak levels usually occur no later than 8 AM as a consequence of the normal circadian rhythm.³⁸ Thus, measuring early morning cortisol concentration any later than 8 AM will reduce the sensitivity for detection, and measuring in a 2-hour window between 8 and 10 AM is even less sensitive. This explains the results of studies where there has been only a small detectable effect on early morning cortisol concentration measured at a variable time between 8 and 10 AM in patients receiving fluticasone.^32-35,39-41 Although a given end point of tissue response may be highly sensitive at detecting systemic bioactivity, these effects should be put into proper perspective in terms of clinically relevant adverse effects. The use of knemometry (an electronic method for measuring lower-leg growth) to measure small differences in lower-leg length is a good example of a test that is highly sensitive as a short-term marker of systemic bioactivity in children but does not predict effects of inhaled corticosteroids on long-term growth.

RESULTS

Jump to Section  • Top  • Introduction  • Materials and methods  • Results  • Comment  • Author information  • References

ADRENAL SUPPRESSION

The administration of exogenous inhaled corticosteroids results in a negative feedback effect on glucocorticoid receptors in the anterior pituitary gland and hypothalamus, which in turn suppresses levels of corticotropin-releasing hormone and corticotropin, respectively, and a consequent reduction in cortisol secretion from the adrenal cortex. Prolonged suppression of corticotropin levels eventually results in atrophy of the adrenal cortex. The presence of low endogenous cortisol levels is not clinically relevant, providing there is additional glucocorticoid activity due to the presence of exogenous corticosteroid in the systemic circulation. The presence of adrenal cortical atrophy becomes clinically relevant if exogenous corticosteroid therapy is abruptly stopped, or if there is an intercurrent stressful stimulus (eg, surgery, trauma, infection, myocardial infarction), whereby the adrenal cortex is incapable of mounting a sufficient endogenous cortisol response, resulting in an acute adrenal insufficiency crisis.³⁸ A summary of studies that have evaluated at least 3 doses of inhaled corticosteroid on variables of adrenal suppression in asthmatic children and adults is shown in Table 1.

View this table: [in this window] [in a new window] Table 1. Dose Response for Adrenal Suppression in Asthmatics*

In general terms, there are 2 types of tests of adrenocortical function, namely, screening tests of basal adrenocortical activity and dynamic stimulation tests to assess adrenocortical reserve. The most sensitive way to evaluate basal adrenocortical activity is to perform a 24-hour integrated measurement of plasma cortisol levels or urinary free cortisol excretion.³⁸ The repeated measurement of plasma cortisol levels for 24 hours is clearly impractical as a routine screening test and is therefore only used in a controlled laboratory research environment. Proper compliance with 24-hour urine collection is also difficult to achieve in an outpatient setting, and hence fractionated overnight and early morning urinary cortisol collections may be used to overcome this problem. This technique can be further refined by correcting the urinary free cortisol excretion for creatinine excretion, being expressed as a urinary cortisol-creatinine ratio. Indeed, the measurement of overnight or early morning urinary cortisol-creatinine excretion has been shown to be as sensitive as an integrated 24-hour urinary free cortisol collection and is more sensitive than a spot measurement of 9 AM plasma cortisol levels.⁵⁸

THE PURPOSE of a dynamic stimulation test with corticotropin or corticotropin-releasing hormone is to assess whether there is any impairment of adrenal cortical reserve that might occur in response to physiological stressful stimuli. When using a synthetic corticotropin (ie, cosyntropin) stimulation test, it is important to use the correct dose that mimics a physiological stress response. In this respect, the conventional 250-g dose of cosyntropin is 500 times the dose required for a stimulated cortisol response, and as such represents a supraphysiological dose of corticotropin.^59-62 The 0.5-g dose of cosyntropin is as effective at producing a stimulated cortisol response and has been shown to correlate well with results of an insulin stress test and is therefore superior to the 250-g dose in detecting impaired adrenal reserve.⁶³

Comparative dose-response studies in healthy volunteers for fluticasone and budesonide given by metered-dose inhaler have shown relative potency ratios (fluticasone-budesonide) of 2.9 and 3.7 for suppression of integrated 24-hour plasma cortisol levels and of 3.1 and 5.2 for suppression of 8 AM plasma cortisol levels.^28-29 This compares with a relative potency ratio of 3.5 for suppression of 8 AM cortisol levels obtained from a dose-response study in asthmatic patients given fluticasone and budesonide via metered-dose inhaler.³¹ In a different study in healthy volunteers, a dose comparison was performed with budesonide and fluticasone given via their respective dry-powder inhaler devices, which showed a relative potency ratio of 1.7 for 24-hour cortisol levels and 2.3 for 8 AM cortisol levels.³⁰ The lower potency ratios for fluticasone vs budesonide when given via dry-powder inhalers reflect the greater drug delivery to the lung from the budesonide Turbuhaler (a reservoir dry-powder inhaler) compared with the fluticasone Diskhaler device (a blister dry-powder device), whereas the fluticasone metered-dose inhaler delivers more drug than the budesonide metered-dose inhaler.⁶⁴ The reason for the higher ratio with 8 AM than with 24-hour cortisol levels probably reflects the longer elimination half-life of fluticasone, such that there will be higher levels of fluticasone at 8 AM when used with a 12-hour dosing interval.

When comparing both drugs given via the metered-dose inhaler device, assuming half the dose of fluticasone is therapeutically equivalent to 1 dose of budesonide, this would result in fluticasone exhibiting approximately 1.7-fold greater systemic activity, on the assumption of a relative potency ratio of 3.5:1 for cortisol suppression. The budesonide Turbuhaler and fluticasone Diskhaler are therapeutically equivalent on a milligram-for-milligram basis, whereas the fluticasone Diskhaler exhibits 1.7-fold greater adrenal suppression than the budesonide Turbuhaler.^{30, 45} This shows that differences in glucocorticoid receptor potency alone cannot account for the 1.7-fold greater adrenal suppression seen with fluticasone. The greater degree of systemic bioactivity with fluticasone probably represents a complex interplay of factors, including accumulation in blood, retention in systemic tissue, and prolonged receptor occupancy.

These studies do not provide information on the relative therapeutic index of each drug, as there is no commensurate evaluation of antiasthmatic clinical efficacy. In the study by Ayres et al³⁹ of patients with severe asthma, doubling the 1-mg/d dose of fluticasone propionate resulted in no improvement in antiasthmatic efficacy, but was associated with a highly significant increase in adrenal suppression. This suggests that even for high-potency drugs such as fluticasone propionate, there is likely to be a greater falloff in the risk-benefit ratio for doses above 1 mg/d. In the same study, 2-mg/d fluticasone propionate was no more effective than 1.6 mg of budesonide, but was associated with a significantly greater level of cortisol suppression, indicating that in patients with severe asthma, the use of a higher-potency drug may not necessarily be associated with an improvement in the therapeutic index.

The effects of inhaled corticosteroids have also been compared with those of oral corticosteroids in dose-response studies. In a dose-ranging study in asthmatic patients, fluticasone propionate (0.44-1.76 mg/d) given via large-volume spacer produced dose-related suppression of 8 AM cortisol levels, which was comparable to that of prednisolone (5-20 mg/d), with maximal suppression amounting to 56% with fluticasone propionate (1.76 mg) vs 67% with oral prednisolone (20 mg).⁶⁵ The calculated relative milligram potency ratio for fluticasone vs prednisolone was 8.5:1 (95% CI, 5.7-11.2). Toogood et al⁶⁶ compared oral prednisone and inhaled budesonide (via large-volume spacer) in terms of their relative efficacy and cortisol suppression. In patients who were not dependent on prednisone, the relative potency ratio (budesonide vs prednisone) for efficacy was 56:1, with the relative ratio for cortisol suppression being 9:1, resulting in a relative therapeutic index of 6:1. In patients who were dependent on prednisone, the ratios for efficacy and cortisol suppression were 60:1 and 8:1, respectively, resulting in a relative therapeutic index of 7:1.

With all inhaled corticosteroids given at high dosage, there is likely to be a dual effect due to topical bioactivity from the airway dose as well as prednisonelike activity from the systemic bioavailable dose. The component of systemic bioactivity is therefore likely to be greater with fluticasone, which along with its topical potency may contribute to its antiasthmatic effects when given at high doses. This may partially explain why it is possible to wean patients from oral prednisone maintenance therapy by using high-dose inhaled fluticasone. In other words, systemic prednisone is being substituted with systemic fluticasone. This is supported by the observation of a persistent degree of cortisol suppression in patients who are weaned from prednisone therapy by treatment with high-dose fluticasone propionate (2 mg/d).⁶⁷ After 16 weeks of treatment with fluticasone, despite weaning to a mean prednisone dose of only 0.9 mg/d, there were persistently abnormal early morning cortisol values in 73% of patients, although this was associated with a 22% improvement in morning peak flow. This suggests that patients who are weaned from oral prednisone therapy with high-dose inhaled corticosteroids should be closely monitored for evidence of persistent impaired adrenal function, and particularly when using high-potency drugs such as fluticasone.

Most studies in asthmatic children have shown that with doses of inhaled corticosteroid of 0.4 mg/d or less, irrespective of drug or delivery device, there is no evidence of detectable adrenal suppression.^{48-49,52, 55-57,68-85} There are, however, 2 noteworthy exceptions. First, Agertoft and Pedersen⁶⁸ showed that dry-powder formulations of fluticasone propionate and budesonide, in doses of 0.2 mg/d and 0.4 mg/d, respectively, for 2 weeks, produced significant suppression of 24-hour urinary cortisol-creatinine excretion, with fluticasone causing greater suppression. Second, Nicolaizik et al⁷⁵ showed that budesonide and beclomethasone dipropionate (given via metered-dose inhaler) at 0.4 mg/d for 2 weeks produced comparable suppression of integrated overnight serum cortisol profile and 24-hour urinary free cortisol levels, although this study was open and not placebo controlled. Studies of doses greater than 0.4 mg/d given via spacer have shown fluticasone propionate and beclomethasone dipropionate to produce greater suppression of urinary cortisol-creatinine excretion than budesonide.^{49, 56-57} These findings once again emphasize the importance of always trying to taper doses to attain the lowest possible maintenance dose for adequate long-term asthma control in children.

It is probably more clinically relevant to look at individual data for abnormally low cortisol values rather than to evaluate the statistical significance of mean responses. For the reasons discussed previously, it is pertinent to evaluate absolute cortisol values in studies of asthmatic patients but not in healthy volunteers. In a study by Clark et al⁴⁹ of asthmatic children, 18 of 30 patients had low cortisol values when given fluticasone propionate compared with 6 of 30 when given budesonide, in terms of overnight urinary cortisol excretion, when both drugs were given via a large-volume spacer with a dose range of 0.4 to 1.25 mg/d. In adult asthmatics, 21 of 36 had low overnight urinary cortisol measurements when given fluticasone propionate vs 3 of 36 when given budesonide, when both drugs were given with a dose range of 0.5 to 2.0 mg/d via metered-dose inhaler alone.³¹ In the same study, for doses of up to 1 mg/d, 14 of 24 vs 1 of 24 had low cortisol values when given fluticasone propionate and budesonide, respectively.

The likelihood of impaired adrenal reserve and insufficient cortisol response to stress can be evaluated using a dynamic stimulation test. Smith and Hodson⁸⁶ studied 54 asthmatic adults receiving long-term beclomethasone dipropionate therapy via metered-dose inhaler in doses ranging from 0.5 to 2.0 mg/d with no concurrent oral corticosteroid therapy. Evidence of adrenal suppression was found in terms of subnormal plasma cortisol levels before and after stimulation with 250 µg of cosyntropin in 4 of 11 patients taking 2.0 mg/d. Brown et al⁸⁷ studied a group of 78 adults with asthma who had been receiving long-term inhaled corticosteroid therapy, with evidence of adrenal suppression being identified at results of screening in 16 of the patients who were taking high-dose beclomethasone dipropionate (1.5-2.0 mg/d) and 10 who had received previous long-term systemic steroid therapy. Fourteen of 16 patients had subnormal cortisol values after cosyntropin stimulation (250 µg), with 12 of these patients also having subnormal 24-hour urinary cortisol excretion. In a multicenter parallel group study of 143 adults with asthma given 6-month treatment with 0.8, 1.2, or 1.6 mg/d of triamcinolone acetonide via spacer, all doses produced significant suppression of mean 24-hour urinary free cortisol levels but had no significant effect on mean 8 AM plasma cortisol levels or the response to cosyntropin stimulation (250 µg).⁵⁴ These data are consistent with the findings of Wilson et al,⁸⁸ where triamcinolone acetonide, 1.6 mg/d, or flunisolide acetate, 2 mg/d, produced significant suppression of overnight and early morning urinary cortisol-creatinine excretion, but exhibited no significant effect on 8 AM cortisol levels or on response to cosyntropin stimulation (0.5 µg).

META-ANALYSIS OF ADRENAL SUPPRESSION STUDIES

A meta-analysis of 21 studies of urinary cortisol levels (Figure 1) and 13 studies of suppression of 8 AM plasma cortisol levels (Figure 2) revealed fluticasone to exhibit significantly steeper dose-related systemic bioactivity than beclomethasone, budesonide, or triamcinolone. The variables from the regression analysis are shown in Table 2 and Table 3 for urinary and for plasma cortisol suppression, respectively. There were significant differences between the slope gradients for urinary cortisol levels when comparing fluticasone with beclomethasone, triamcinolone, or budesonide; whereas for 8 AM plasma cortisol level, the slope for fluticasone was significantly different than that for budesonide or triamcinolone. There were no significant differences among beclomethasone, budesonide, or triamcinolone for their effects on urinary or plasma cortisol levels.

View larger version (22K): [in this window] [in a new window] Figure 1. Meta-analysis of 21 studies that evaluated effects on 24-hour or overnight urinary cortisol levels.23, 31, 42, 44, 46, 49-50,54, 56, 58, 68, 70, 72-73,75, 88-93 The scale depicts doubling doses of inhaled corticosteroid. The data were analyzed using multiple regression analysis of slopes, depicting the line of best fit for each drug. The slope gradient for fluticasone propionate was significantly different compared with beclomethasone dipropionate (P<.05), triamcinolone acetonide (P<.05), or budesonide (P<.001). There were no significant differences among beclomethasone, triamcinolone, and budesonide.

View larger version (21K): [in this window] [in a new window] Figure 2. Meta-analysis of 13 studies that evaluated effects on 8 AM plasma and serum cortisol levels.28-31,42, 44, 46, 54, 65, 88, 92, 94-95 For the purposes of clarity, the scale was plotted on a putative dose equivalence of 10:1 mg for oral vs inhaled corticosteroid (shown as doubling doses). Multiple regression analysis showed a significant difference in slope gradients (shown as line of best fit) between fluticasone propionate vs budesonide (P<.001) or triamcinolone acetonide (P<.005). There was also a significant difference in slope between prednisolone vs budesonide (P<.05) or triamcinolone (P<.05). The slope for prednisolone was not significantly different (P=.76) from that of fluticasone.

View this table: [in this window] [in a new window] Table 2. Regression Variables for Urinary Cortisol Suppression*

View this table: [in this window] [in a new window] Table 3. Regression Variables for 8 AM Plasma Cortisol Suppression*

These effects were most apparent at doses above 0.8 mg/d, due to the differences in slope gradients between fluticasone and the other drugs. It was also evident from the data on 8 AM plasma cortisol suppression that there were no significant differences in slopes between fluticasone and prednisolone when both drugs were compared on a putative 1:10-mg equivalent basis. As differences between fluticasone and the other inhaled corticosteroids were not parallel across the dose range, this indicated that a difference in glucocorticoid receptor potency was probably not the main reason for the greater systemic bioactivity exhibited by fluticasone. When comparing the same degree of urinary cortisol suppression, it was evident that 1.6 mg of triamcinolone acetonide and 0.4 mg of fluticasone propionate were approximately equivalent.

GROWTH

Any chronic disease process, including asthma, may affect growth. Chronic asthma that is not adequately controlled may result in attenuation of the prepubertal growth spurt, a delay in puberty and the associated pubertal growth spurt, followed by a catch-up phase toward final attained adult height. The effect of the asthmatic disease process itself thus may have an important confounding effect in interpreting effects on growth due to exogenous corticosteroid therapy. Normal growth occurs rapidly during the first 3 years of life and is predominantly determined by nutritional status. This is then followed by childhood growth up until puberty, dependent on growth hormone secretion from the anterior pituitary gland, followed by the pubertal growth spurt, which is also driven by the sex steroid hormones.

The most important outcome measure is long-term growth as assessed by final adult height and compared with the predicted values for sex and midparental height. In practice, this type of longitudinal type cohort follow-up studies is difficult to perform. Thus, most studies have evaluated effects on medium-term growth for a period of months or years using a calibrated stadiometer to measure height (Table 4). The main outcome measures of such studies are usually expressed as the height velocity (or growth rate) or statural height compared with sex- and age-matched normal standards, expressed as height standard deviation score or height centiles. Such measurements are affected by growth rate during childhood, seasonal effects of growth, and timing of the pubertal growth spurt. For this reason, results of medium-term growth studies may not predict effects on final attained adult height.

View this table: [in this window] [in a new window] Table 4. Medium and Long-term Controlled Growth Studies*

It is also important to consider the effects of corticosteroids on bone age as well as growth rate. Providing that growth rate and bone age are reduced to a comparable degree, the child may retain the full potential for catch-up growth to achieve normal predicted adult height. If growth rate is attenuated more than bone age, it is possible that final height may be adversely affected.

Long-term maintenance therapy with oral corticosteroids is known to suppress growth in children. Current guidelines for the treatment of childhood asthma now suggest the use of early intervention with inhaled corticosteroids as the mainstay of preventive therapy, as this has been shown to prevent disease progression in terms of reversible airway damage as a consequence of untreated inflammation. For most children with asthma, effective long-term control can be achieved with low doses of inhaled corticosteroids (<0.4 mg/d), which are associated with minimal, if any, detectable systemic bioactivity.

Studies measuring short-term lower-leg growth using knemometry have shown that dose-related suppression with inhaled corticosteroids occurs to a lesser degree than with oral prednisolone. In general, studies of inhaled corticosteroids have shown detectable effects on knemometry at doses of 0.4 mg/d or above.^{68, 107-110} It has been shown subsequently that short-term effects on knemometry do not predict effects on long-term growth using a properly calibrated stadiometer to measure statural height.¹¹¹ Thus, knemometry should be regarded merely as a highly sensitive marker of potential systemic bioactivity but not a clinically relevant measure of growth effects with inhaled corticosteroids.

Two 12-month studies comparing monotherapy with dry-powder beclomethasone dipropionate, 0.4 mg/d, and salmeterol xinafoate, 50 g twice daily, showed beclomethasone to be superior in terms of disease control and airway hyperreactivity, although it was associated with a small but significant reduction in height velocity of 1.08 to 1.40 cm/y.^99-100 In another 12-month study comparing monotherapy with beclomethasone dipropionate via pressurized metered-dose inhaler, 0.336 mg/d, or optimized twice-daily theophylline, beclomethasone resulted in comparable symptom control with less bronchodilator use, fewer rescue courses of systemic steroids, and fewer side effects, although beclomethasone resulted in a 1.6-cm/y reduction in height velocity that was most pronounced in boys.¹⁰³ A 7-month study also showed a 1-cm reduction in height velocity comparing dry-powder beclomethasone dipropionate, 0.4 mg/d, and placebo, although this was not associated with any detectable effect on urinary cortisol levels or biochemical bone markers.⁷² However, in a meta-analysis of 12 other medium-term studies with beclomethasone dipropionate (dose range, 0.2-0.9 mg/d), there was no association between its use and adverse growth effects, in contrast to significant growth impairment observed in 8 studies with prednisone.¹¹²

Agertoft and Pedersen¹⁰² performed a prospective cohort follow-up study of 216 asthmatic children during a 3- to 7-year period after an initial 1- to 2-year washout period without any corticosteroid exposure. During the follow-up period, the mean daily dose of budesonide was tapered from 0.71 to 0.43 mg in association with a marked improvement in asthma control and lung function. At the same time, there was no overall effect in the budesonide group on height velocity or standard deviation score compared with the initial lead-in period or matched asthmatic controls receiving no corticosteroid therapy. In a 4-year cohort follow-up of 2355 children aged 1 through 15 years, those receiving doses of inhaled corticosteroid greater than 0.4 mg/d who required general practice or hospital services exhibited a significant reduction in their stature.⁹⁸ This effect was independent from but smaller than the effect of socioeconomic deprivation. This suggests that other factors, such as nutritional status, may be more relevant than any small putative effect of drug therapy.

There are only 2 long-term studies that have looked at final adult height in children receiving inhaled corticosteroids. Balfour-Lynn¹¹³ showed that although puberty was delayed, treatment with beclomethasone dipropionate, 0.4 to 0.6 mg/d, did not adversely affect subsequent catch-up growth, which resulted in the attainment of normal predicted adult height. In a more recent prospective cohort study, 153 patients with asthma, of whom 58 were receiving corticosteroid therapy, were compared with 153 age- and sex-matched nonasthmatic controls.¹⁰¹ The adult height of asthmatic children adjusted for midparental height was not significantly different from that of controls, and there was also no significant overall effect of inhaled or oral corticosteroid exposure. These results of long-term follow-up studies are therefore reassuring and suggest that suppressing asthmatic disease activity in children will usually outweigh any potential systemic bioactivity of inhaled corticosteroids in determining long-term growth. However, it is worth mentioning that all of the data (published and unpublished) on growth were recently reviewed at a meeting of the Food and Drug Administration Pulmonary-Endocrine Drugs Advisory Committee (Bethesda, Md, July 30-31, 1998), where a consensus decision was made to alter class labeling for all intranasal and inhaled corticosteroids in children to include a precautionary statement that the use of recommended doses may be associated with a reduction in growth velocity.

BONE METABOLISM

One of the greatest concerns of long-term corticosteroid therapy for asthma is its potential for adverse effects on bone turnover, resulting in an increased risk for osteoporosis and fracture. Bone tissue undergoes a constant metabolic turnover and remodeling process throughout adult life. This reflects a fine balance in the bone matrix in terms of the activity of bone-forming (osteoblasts) and bone-breakdown cells (osteoclasts). Uncoupling of this equilibrium of osteoblasts and osteoclasts may cause a reduction in bone mass, resulting in osteoporosis and ultimately increased fracture risk. Corticosteroids tend to affect bone predominantly in the axial skeleton (ie, the vertebrae), which contains a higher proportion of the more metabolically active trabecular bone than cortical bone. The mechanism for corticosteroid-induced bone loss is complex and involves suppression of osteoblast function, increased bone resorption due to attenuated sex hormone secretion, and increased parathyroid hormone levels due to attentuated bowel and renal calcium absorption.

The bone mass at any given time of life represents a complex interplay of genetic loading and other risk factors such as age, ethnic origin, sex, body size, diet, use of alcohol and tobacco, physical activity, thyroid status, and sex hormone status. The radiological measurement of bone mass may be used to assess the risk for development of osteoporosis, when measured at appropriate sites such as the lumbar vertebrae or proximal femur.¹¹⁴ There are, however, a number of sensitive biochemical markers of bone metabolism, although these can be considered only as a surrogate for the criterion standard measurement of bone density. Biochemical markers of bone formation include levels of alkaline phosphatase, osteocalcin, procollagen type 1 carboxyterminal and aminoterminal propeptide, and procollagen type 3 aminoterminal propeptide, all of which are measured in serum. Bone resorption markers include levels of urinary hydroxyproline, urinary or serum pyridinium cross-links, urinary collagen type 1 cross-linked N-telopeptide, urinary collagen type 1 cross-linked C-telopeptide (crosslaps), and serum carboxyterminal telopeptide of type 1 collagen. In general, bone formation markers are more sensitive than bone resorption markers for detecting effects of corticosteroids, with osteocalcin being the marker of choice because of its sensitivity, specificity, and reproducibility.

Short- and medium-term studies of healthy volunteers and asthmatic patients receiving inhaled corticosteroids have been able to detect dose-related effects on biochemical bone markers, which occur less frequently than with oral corticosteroids.^{35, 41-42,65, 94-95,115-126} In the study of Jennings et al,⁹⁴ from the steep part of the dose-response curves it was possible to calculate relative potency ratios on a milligram equivalent basis for budesonide vs prednisolone, showing a ratio of 2.9:1 for osteocalcin suppression and 5.0:1 for cortisol suppression. These data therefore suggest that it may not be possible to extrapolate directly the systemic effects of corticosteroids from one tissue to another, and if anything, bone metabolism may be relatively more resistant to the adverse effects to corticosteroid therapy. Cross-sectional studies in asthmatic patients receiving long-term beclomethasone or budesonide therapy have shown lower osteocalcin levels compared with controls not receiving inhaled corticosteroid.^{119, 121, 125} However, bone markers cannot be used as a surrogate for bone density to predict the risk for development of osteoporosis.

There are surprisingly few long-term controlled studies that have evaluated effects of corticosteroids on bone density in asthmatic children or adults (Table 5). In 157 asthmatic children receiving inhaled budesonide for 3 to 6 years, bone density measurement was not significantly different compared with that in asthmatic controls who had not received steroids.⁹⁶ There was also no relationship between bone density and duration of treatment or in terms of current and accumulated dose of budesonide. In a cross-sectional study of asthmatic adults receiving long-term corticosteroid therapy, there was a decrease in bone density that was associated with the daily dose of inhaled corticosteroid and years of prednisone use.¹²¹ In a subgroup analysis of 41 postmenopausal asthmatic women from this study, increased bone density was found to be associated with the number of years of supplemental estrogen therapy, suggesting that this may have a protective effect against corticosteroid-induced osteoporosis in this high-risk group of patients.

View this table: [in this window] [in a new window] Table 5. Controlled Studies of Bone Density in Asthmatic Children and Adults*

More recently, Wisniewski et al¹¹⁹ found no difference in bone density between asthmatic patients taking corticosteroids and unmatched asthmatic controls who were not taking inhaled corticosteroids. In this study, there was an association between the cumulative inhaled dose of corticosteroid and reduced lumbar bone density, but only in women. Ip et al¹³⁰ also showed reduced bone density in asthmatics receiving inhaled corticosteroids compared with nonasthmatic controls, the effect being predominantly observed in women. There was also an association of daily dose of inhaled corticosteroids and reduced lumbar bone density in asthmatic women. Many of the studies looking at bone density are difficult to interpret because of their relatively small sample size or because of confounding due to the legacy of previous oral corticosteroid exposure. However, postmenopausal asthmatic women are at particular risk and should if possible receive concomitant estrogen replacement therapy, which also has other benefits in terms of mood, skin, and vascular sequelae.

OCULAR EFFECTS

The use of systemic corticosteroids is an established risk factor in the development of posterior subcapsular cataracts. In a review published in 1986 surveying 9 previous studies among 343 asthmatics treated with corticosteroids, the prevalence of posterior subcapsular cataracts was found to range from 0% to 54%, with an average of 9%.¹³⁴ The prevalence was influenced by the daily cumulative dose of corticosteroids as well as by age and ethnic origin. Previous case reports of posterior subcapsular cataracts in patients taking inhaled corticosteroids are often confounded by previous exposure to oral corticosteroid therapy.^135-137 Indeed, resolution of posterior subcapsular cataracts has occasionally been observed after conversion from maintenance prednisone to inhaled corticosteroid therapy, suggesting a possible dynamic component in early cases.^138-139

Toogood et al¹⁴⁰ studied 48 patients (mean age, 61 years) receiving long-term inhaled budesonide or beclomethasone dipropionate with a mean dose of 1.5 mg/d, and found a 27% prevalence of posterior subcapsular cataracts as well as a correlation of the dose and duration of prednisone but not inhaled corticosteroid therapy. Simons et al¹⁴¹ found no posterior subcapsular cataracts in 95 patients with asthma (mean age, 13.8 years), with a mean dose of budesonide or beclomethasone dipropionate of 0.75 mg/d for a mean duration of 5 years, in whom 77% had no exposure to oral corticosteroids in the past year. Abuekteish et al¹⁴² found no association of posterior subcapsular cataracts with inhaled corticosteroid use in 140 patients with asthma (mean age, 12.2 years) with a treatment duration of more than 5 years, and only 1 patient who was receiving frequent prednisone therapy had cataracts.

More recently, Cumming et al¹⁴³ conducted a population-based cross-sectional study that identified 370 patients using inhaled corticosteroids. In these subjects, after adjustment for age and sex, the relative prevalence ratio for corticosteroid vs no corticosteroid exposure was 1.9 (95% CI, 1.3-2.8) for posterior subcapsular, 1.5 (95% CI, 1.2-1.9) for nuclear, and 1.1 (95% CI, 0.9-1.3) for cortical cataracts. The relative prevalence ratio of posterior subcapsular cataracts for a lifetime dose of beclomethasone greater than 2000 mg was 5.5 (95% CI, 2.3-13.0). This study suggests an increased risk for posterior subcapsular cataracts in patients receiving long-term high-dose inhaled corticosteroid therapy, at least with beclomethasone dipropionate. Nonetheless, the relative risk is likely to be lower with high-dose inhaled corticosteroid compared with oral prednisone therapy, in terms of the relative doses required for comparable long-term asthma control.

There have also been case reports suggesting that systemic bioactivity of inhaled or intranasal corticosteroids might result in ocular hypertension or open-angle glaucoma.^144-145 This was investigated in a recent case-control study of 9793 patients with open-angle glaucoma or ocular hypertension, compared with 38,325 randomly selected controls.¹⁴⁶ Odds ratios for ocular hypertension or open-angle glaucoma were determined in patients using inhaled or intranasal glucocorticosteroids relative to nonusers, adjusted for age, sex, diabetes, systemic hypertension, and the use of ophthalmic or oral corticosteroids. Overall results showed that there was no association between current use of inhaled or intranasal corticosteroids and an increased risk for ocular hypertension or open-angle glaucoma. However, those patients who were currently using high doses of corticosteroids on a regular basis for 3 or more months were at a small, significantly increased risk, with a calculated odds ratio of 1.44 (95% CI, 1.01-2.06). It would therefore seem prudent for patients receiving long-term, high-dose inhaled corticosteroid therapy (>1.5 mg/d or >0.75 mg/d of fluticasone) to have regular annual or biennial ophthalmic checkups to monitor for ocular hypertension or posterior subcapsular cataracts.

SKIN EFFECTS

Thinning and bruising of the skin may occur while taking inhaled corticosteroids, with evidence of a dose-response effect. Capewell et al¹⁴⁷ performed ultrasound skin thickness measurements and a clinical assessment of bruising in 68 patients receiving long-term oral prednisolone (n=15; 5-20 mg/d), high-dose inhaled beclomethasone dipropionate (n=21; 1-2.5 mg/d), or low-dose inhaled beclomethasone dipropionate (n=15; 0.2-0.8 mg/d) and in control subjects. The prevalence of bruising was 12% in controls, 33% in patients taking low-dose inhaled beclomethasone, 48% in patients taking high-dose inhaled beclomethasone, and 80% in patients taking prednisolone. Compared with controls, the measured skin thickness was 28% to 33% less in patients taking prednisolone and 15% to 19% less in patients taking high-dose beclomethasone, but no significant difference was seen in patients taking low-dose beclomethasone. The results of this study were strengthened in that patients receiving low-dose beclomethasone had not received long-term high-dose beclomethasone or prednisolone therapy, whereas the patients receiving high-dose beclomethasone had never received long-term prednisolone treatment.

In a questionnaire-based survey, Mak et al¹⁴⁸ reported on bruising tendency in a group of 202 asthmatic patients taking inhaled corticosteroids compared with an age- and sex-matched group of asthmatic patients not taking inhaled corticosteroids. The prevalence of bruising was significantly greater in the patients using inhaled corticosteroids, although there was a particular tendency in older men receiving high-dose therapy. Roy et al¹⁴⁹ studied 100 adult asthmatic patients taking high doses of inhaled beclomethasone dipropionate or budesonide (0.8-2 mg/d) for at least 3 months compared with 100 age- and sex-matched nonasthmatic controls. Bruising was assessed using questionnaire and skin examination, and there was also a concomitant evaluation of 24-hour urinary cortisol excretion. The prevalence of bruising in asthmatic patients was 71% and 48% by questionnaire and examination, respectively, compared with a prevalence of 32% and 48%, respectively, for controls. There was a greater likelihood of skin bruising developing in older women. Furthermore, a higher number of bruising lesions on direct examination was associated with lower levels of urinary cortisol excretion. Comparable data on skin bruising are not available for the higher-potency inhaled corticosteroids such as fluticasone, although one might expect from first principles that bruising would occur at lower doses than with beclomethasone or budesonide.

The presence of skin bruising can be considered a visible marker of the adverse effects of corticosteroids on collagen turnover in connective tissue, and serial skin examinations therefore can be used to monitor potential systemic adverse effects in patients taking high-dose therapy. However, it is unclear whether early susceptibility to skin bruising relates to effects on collagen in other systemic tissues such as bone, and so the absence of skin bruising cannot be taken as a guide to the safety of a given dose of inhaled corticosteroid. Nonetheless, the presence of bruising points to the possibility of systemic effects developing elsewhere in bodily tissues.

COMMENT

Jump to Section  • Top  • Introduction  • Materials and methods  • Results  • Comment  • Author information  • References

There is no doubt that, compared with long-term oral prednisone maintenance therapy, the use of inhaled corticosteroids has improved the benefit-risk ratio for the preventive treatment of asthma vastly. However, the trend toward the earlier use of inhaled corticosteroids, particularly in children, makes it even more important to appraise critically their potential for producing systemic adverse effects during long-term administration.

Meta-analysis reveals fluticasone propionate to exhibit greater dose-related adrenal suppression than other available inhaled corticosteroids, particularly at doses above 0.8 mg/d. These differences cannot be accounted for by enhanced potency alone when comparing therapeutically equivalent doses, and probably represent the particular pharmacokinetic properties of fluticasone. There is considerable interindividual susceptibility to systemic effects of inhaled corticosteroids, so that it is difficult to predict whether systemic effects will develop in an individual at a given dose of inhaled corticosteroids.

The potential for systemic adverse effects with high-dose inhaled corticosteroids will become increasingly relevant, as there are now effective alternative nonsteroidal therapies, including the long-acting ₂-agonists, theophyllines, and antileukotrienes, that may permit the use of a lower dose of inhaled corticosteroid when used as additive therapy. For the small proportion of patients who are dependent on high-dose inhaled corticosteroid therapy, it would seem prudent to perform regular annual or biennial checks for evidence of systemic adverse effects on skin, bone, eye, adrenal gland, and growth. The most rational approach is to minimize the potential systemic burden by always trying to taper to the lowest effective maintenance dose of inhaled corticosteroid, to achieve optimal long-term asthma control and quality of life.

AUTHOR INFORMATION

Jump to Section  • Top  • Introduction  • Materials and methods  • Results  • Comment  • Author information  • References

Accepted for publication September 10, 1998.

The author wishes to thank Jenny Orr for helping to prepare the manuscript and Simon Ogston, PhD, for statistical advice with the meta-analysis.

Reprints: Brian J. Lipworth, MD, FRCPE, Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, Scotland (e-mail: b.j.lipworth{at}dundee.ac.uk).

From the Department of Clinical Pharmacology and Therapeutics and Respiratory Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland.

REFERENCES

Jump to Section  • Top  • Introduction  • Materials and methods  • Results  • Comment  • Author information  • References

1. The British guidelines on asthma management: 1995 review and position statement. Thorax. 1997;52(suppl 1):S1-S21. 2. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health; 1997. Publication 97-4051. 3. Lipworth BJ. Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Pulm Pharmacol. 1996;9:19-27. FULL TEXT | ISI | PUBMED 4. Johannsson SA, Anderson FE, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. Eur J Clin Pharmacol. 1982;22:523-529. FULL TEXT | ISI | PUBMED 5. Phillips GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med. 1990;84(suppl A):19-23. 6. English AF, Neate MS, Quint DJ, Sareen M. Biological activities of some corticosteroids used in asthma [abstract]. Am J Respir Crit Care Med. 1994;149(pt 2):A212. 7. Andersson N, Klint S, Randwall G, Wiren JE. Equipotency of budesonide and fluticasone propionate in the vasoconstriction assay [abstract]. Am J Respir Crit Care Med. 1994;149(pt 6):A467. 8. Dahlberg E, Thalen A, Brattsand R, et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16alpha, 17alphaacetal-substituted glucocorticoids. Mol Pharmacol. 1984;25:70-78. ABSTRACT 9. Wurthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. J Pharm Ztg Wiss. 1992;4:161-167. 10. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids. 1994;59:597-602. FULL TEXT | ISI | PUBMED 11. Miller-Larsson A, Mattsson H, Ohlsson S, et al. Prolonged release from the airway tissue from glucocorticoids budesonide and fluticasone propionate as compared to beclomethasone dipropionate [abstract]. Am J Respir Crit Care Med. 1994;149(suppl 4):A466. 12. Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1997;43:155-161. FULL TEXT | ISI | PUBMED 13. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996;42:697-705. FULL TEXT | ISI | PUBMED 14. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davis P, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis. 1982;63(suppl 122):86-95. 15. Harding SM. The human pharmacology of fluticasone propionate. Respir Med. 1990;84(suppl A):25-29. 16. Heald D, Argenti D, Jensin B, Ferccaro S. Disposition of 14c triamcinolone acetonide administered as single oral dose of 100 Ci to healthy volunteers. In: Proceedings of a joint meeting of the American Academy of Allergy, Asthma Immunology and the American Thoracic Society, in cooperation with the American College of Chest Physicians, Asthma 1995 Conference, Theory to Treatment; July 15-17, 1995; Chicago, Ill. Page 14. 17. Chaplin MD, Rooks W, Swenson EW, Cooper WC, Neranberge C, Schu NI. Flunisolide metabolism and dynamics of a metabolite. J Allergy Clin Immunol. 1980;27:402-413. 18. Andersson P, Ryrfeldt A. Biotransformation of the topical glucocorticoids, budesonide and beclomethasone, 17,21-diaproprionate in human liver and lung homogenate. J Pharm Pharmacol. 1984;36:763-765. ISI | PUBMED 19. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered dose inhaler (P-MDI). Eur Respir J. 1998;7:1839-1844. 20. Derendorf H, Hochhaus G, Rohatagi S. Pharmacokinetics of triamcinolone acetonide after intravenous, oral and inhaled administration. J Clin Pharmacol. 1995;35:302-305. ABSTRACT 21. Falcoz Z, Kergy SM, Smith J, Olsson P, Ventresca GP. Pharmacokinetics and systemic exposure of inhaled beclomethasone dipropionate [abstract]. Eur Respir J. 1996;9(suppl 23):162S. 22. Grahnen A, Eckernas SA, Brundin RM, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol. 1994;38:521-525. ISI | PUBMED 23. Lonnebo A, Grahnen A, Jansson B, Brunden RM, Ling-Andersson A. An assessment of the systemic effects of single repeated doses of inhaled fluticasone propionate, in inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol. 1996;49:459-463. FULL TEXT | ISI | PUBMED 24. Brown PH, Blundell G, Greening AP, Crompton GK. Do large volume spacer devices reduce systemic effects of high dose inhaled corticosteroids. Thorax. 1990;45:736-739. FREE FULL TEXT 25. Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry-powder inhaler. Thorax. 1991;46:891-894. FREE FULL TEXT 26. Brown PH, Matusiewicz S, Seharing C, Tibi L, Greening AP, Crompton GK. Systemic effects of high dose inhaled steroids: comparison of beclomethasone and budesonide in healthy subjects. Thorax. 1993;48:967-973. FREE FULL TEXT 27. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johannsson SA. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis. 1983;129:723-729. ISI 28. Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J. 1996;9:1427-1432. ABSTRACT 29. Donnelly R, Williams KM, Baker B, Badcock CA, Day RO, Seal JP. Effects of budesonide and fluticasone on 24-hour plasma cortisol: a dose-response study. Am J Respir Crit Care Med. 1997;156:1746-1751. FREE FULL TEXT 30. Grahnen A, Jansson B, Brunden RM, et al. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Eur J Clin Pharmacol. 1997;52:261-267. FULL TEXT | ISI | PUBMED 31. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax. 1997;52:55-58. FREE FULL TEXT 32. Barnes NC, Marone G, Di Maria GV, Visser S, Utama I, Payne SI. A comparison of fluticasone propionate 1 mg daily, with beclomethasone dipropionate 2 mg daily, in the treatment of severe asthma. Eur Respir J. 1993;6:877-884. ABSTRACT 33. Lundback B, Alexander M, Day J, et al. Evaluation of fluticasone propionate (500 µg/day) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone type propionate (1000 µg/day) administered by pressurized inhaler. Respir Med. 1993;87:609-620. FULL TEXT | ISI | PUBMED 34. Lorentzen KA, Van Helmon JLM, Bauer K, Langaker KE, Bonifazi F, Harris TAG. Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison of 1 year. Respir Med. 1996;90:609-617. FULL TEXT | ISI | PUBMED 35. Bootsma GP, Dekhuijzen R, Festen J, Mulder PGH, Swinkels LMJW, van Herwaarden CLA. Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Am J Respir Crit Care Med. 1996;153:924-930. ABSTRACT 36. Lipworth BJ, Clark DJ. Effects of airway calibre on the lung delivery of nebulised salbutamol. Thorax. 1997;52:1036-1039. ABSTRACT 37. Knutsson PU, Stierna P, Marcus C, Carlstedt-Duke J, Carlstrom K, Bronregard M. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol. 1995;144:401-410. 38. Lipworth BJ, Seckl JL. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax. 1997;52:476-482. ISI | PUBMED 39. Ayres JG, Bateman ED, Lundback B, Harris TAJ. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J. 1995;8:579-586. ABSTRACT 40. Fabbri L, Burge PS, Croonenburgh L, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax. 1993;48:817-833. FREE FULL TEXT 41. Grove A, Allam C, McFarlane LC, McPhate G, Jackson CM, Lipworth BJ. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol. 1994;38:527-532. ISI | PUBMED 42. Lipworth BJ, Wilson AM. Dose response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adults [abstract]. J Allergy Clin Immunol. 1998;101(pt 2):S6. 43. Lawrence M, Wolfe J, Webb RD, et al. Efficacy of inhaled fluticasone propionate in asthma results from topical and not systemic activity. Am J Respir Crit Care Med. 1997;156:447-451. 44. Wilson AM, McFarlane LC, Lipworth BJ. Dose response effect for adrenal suppression with repeated twice daily inhaled fluticasone priopionate and triamcinolone acetonide in adult asthmatics. Am J Respir Crit Care Med. 1997;156:1274-1277. FREE FULL TEXT 45. Agertoft L, Pedersen S. A randomised double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. J Allergy Clin Immunol. 1997;99:773-780. FULL TEXT | ISI | PUBMED 46. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax. 1996;51:262-266. FREE FULL TEXT 47. Kellerman DJ, Stricker W, Howland W, et al. Effects of inhaled fluticasone propionate on the HPA-axis of patients with asthma. Eur Respir J. 1996;9(suppl 23):162S. 48. Goldberg S, Algur N, Levi M, et al. Adrenal suppression amongst asthmatic children receiving chronic therapy with inhaled corticosteroid with and without spacer device. Ann Allergy Asthma Immunol. 1996;76:234-238. ISI | PUBMED 49. Clark DJ, Clark RA, Lipworth BJ. Adrenal suppression with inhaled budesonide and fluticasone propionate given by a large volume spacer in asthmatic children. Thorax. 1996;51:941-943. FREE FULL TEXT 50. McCubbin MM, Milavetz G, Grandgeorge S, et al. A bioassay for topical and systemic effect of 3 inhaled corticosteroids. Clin Pharmacol Ther. 1995;57:445-460. 51. Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol. 1994;94:676-683. FULL TEXT | ISI | PUBMED 52. Ninan TK, Reid IW, Carter PE, Smail P, Russell G. Effective high doses of inhaled corticosteroids on adrenal function in children with severe persistant asthma. Thorax. 1993;48:599-602. FREE FULL TEXT 53. Dahl R, Lundback B, Malo JM, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest. 1993;104:1352-1358. FREE FULL TEXT 54. Altman LC, Findlay SR, Lopez M, et al. Adrenal function in adult asthmatics during long-term daily treatment with 800, 1200 and 1600 µg triamcinolone acetonide. Chest. 1992;101:1250-1256. FREE FULL TEXT 55. Priftis K, Milner AD, Conway E, Honor JW. Adrenal function in asthma. Arch Dis Child. 1990;65:838-840. FREE FULL TEXT 56. Bisgaard H, Damkjaer-Nielsen M, Andersen B, et al. Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide. J Allergy Clin Immunol. 1988;81:1088-1095. FULL TEXT | ISI | PUBMED 57. Pedersen S, Fugslang G. Urine cortisol excretion in children treated with high doses of inhaled corticosteroids: a comparison of budesonide and beclomethasone. Eur Respir J. 1988;1:433-435. ABSTRACT 58. McIntyre DH, Mitchell CA, Bowler SD, Armstrong JG, Wooler JA, Cowlie DM. Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens. Thorax. 1995;51:281-284. 59. Broide J, Soferman R, Kivity S, et al. Low dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab. 1995;80:1243-1246. ABSTRACT 60. Brown PH, Blundell G, Greening AP, Crompton GK. Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high doses of inhaled corticosteroid. Respir Med. 1991;85:511-516. ISI | PUBMED 61. Crowley S, Hindmarsh PC, Hownia P, Honor JW, Brook CGD. The use of low doses of ACTH in the investigation of adrenal function in man. J Endocrinol. 1991;130:475-479. FREE FULL TEXT 62. Crowley S, Hindmarsh PC, Honor JW, Brook CGD. Reproducibility of the cortisol response to simulation with a low dose of ACTH (1-24): the effect of basal cortisol levels in comparison of low dose with high dose secretory dynamics. J Endocrinol. 1993;136:167-172. FREE FULL TEXT 63. Rasmuson S, Olsson T, Hagg E. A low dose ACTH test to access the function of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol. 1991;44:151-156. 64. Olsson B. Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers? J Aerosol Med. 1995;8:S13-S19. 65. Wilson AM, Lipworth BJ. Systemic dose-response relationships with oral and inhaled corticosteroid in asthmatics. Thorax. 1997;52(suppl 6):A57. 66. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johannsson SA. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin. 1989;84:688-700. 67. Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisolone use while it improves asthma control and quality of life. Am J Respir Crit Care Med. 1995;152:1467-1473. ABSTRACT 68. Agertoft L, Pedersen S. Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. Eur Respir J. 1997;10:1507-1512. ABSTRACT 69. Yiallouros PK, Milner AD, Conway E, Honor JW. Adrenal function and high dose inhaled corticosteroid for asthma. Arch Dis Child. 1997;76:405-410. FREE FULL TEXT 70. Lipworth BJ, Clark DJ, McFarlane LC. Adrenocortical activity with repeated twice daily dosing of inhaled fluticasone propionate and budesonide given via large volume spacer to asthmatic school children. Thorax. 1997;52:686-689. ABSTRACT 71. Price JF, Russel G, Hindmarsh PC, Wella P, Heaf DP, Williams J. Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Paediatr Pulmonol. 1997;3:178-186. 72. Doull IJM, Freezer NJ, Holgate ST. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med. 1995;151:1715-1719. ABSTRACT 73. Wolthers OD, Pedersen S. Measures of systemic activity of inhaled corticosteroids in children: a comparison of urine cortisol excretion and knemometry. Respir Med. 1995;89:347-349. FULL TEXT | ISI | PUBMED 74. Gustafsson P, Tsanakas J, Gold M, Primhak R, Radfin M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 µg/day with inhaled beclomethasone dipropionate 400 µg/day in mild and moderate asthma. Arch Dis Child. 1993;69:206-211. FREE FULL TEXT 75. Nicolaizik WH, Marchant JL, Preece MA, Warner JO. Endocrine and lung function in asthmatic children treated with inhaled budesonide. Am J Respir Crit Care Med. 1994;150:624-628. ABSTRACT 76. Volovitz B, Kauschansky A, Nussinovitch M, Harel L, Varsano I. Normal diurnal variation in serum cortisol concentration in asthmatic children treated with inhaled budesonide. J Allergy Clin Immunol. 1995;96:874-878. FULL TEXT | ISI | PUBMED 77. MacKenzie CA, Weinberg EJ, Tabachnik E, Taylor M, Havnen J, Crescenzi K. A placebo controlled trial of fluticasone propionate in asthmatic children. Eur J Paediatr. 1993;152:856-860. FULL TEXT | ISI | PUBMED 78. Prahl P. Adrenocortical suppression following treatment with beclomethasone and budesonide. Clin Exper Allergy. 1991;21:145-146. 79. Varsano I, Volovitz B, Malik H, Amir J. Safety of 1 year of treatment with budesonide in young children with asthma. J Allergy Clin Immunol. 1990;85:914-920. FULL TEXT | ISI | PUBMED 80. Russell G, Ninan TK, Carter PE, Reid IW, Sutherland I. Effects of inhaled corticosteroids on hypothalamo-pituitary-adrenal function and growth in children. Res Clin Forums. 1989;11:77-86. 81. Prahl P, Jensen T, Bjerregaard-Andersen H. Adrenocortical function in children on high-dose steroid aerosol therapy: results of serum cortisol, ACTH stimulation test and 24 hour urinary free cortisol excretion. Allergy. 1987;42:541-544. ISI | PUBMED 82. Springer G, Avital A, Maayan CH, Rosier A, Godfrey S. Comparison of budesonide and beclomethasone dipropionate for treatment of asthma. Arch Dis Child. 1987;62:815-819. FREE FULL TEXT 83. Baran D. A comparison of inhaled budesonide and beclomethasone dipropionate in childhood asthma. Br J Dis Chest. 1987;81:170-175. FULL TEXT | ISI | PUBMED 84. Law CM, Marchant JL, Honor JW, Preece MA, Warner JO. Nocturnal adrenal suppression in asthmatic children taking inhaled beclomethasone dipropionate. Lancet. 1996;1:942-944. 85. Field HV, Jenkinson PMA, Frame MH, Warner JO. Asthma treatment with a new corticosteroid aerosol budesonide administered twice daily by spacer inhaler. Arch Dis Child. 1982;57:864-866. FREE FULL TEXT 86. Smith MJ, Hodson ME. Effects of long term inhaled high dose beclomethasone dipropionate on adrenal function. Thorax. 1983;38:676-681. FREE FULL TEXT 87. Brown PH, Blundell G, Greening AP, Crompton GK. Hypothalamo-pituitary-adrenal axis suppression in asthmatics taking inhaled high dose corticosteroids. Respir Med. 1990;85:501-510. FULL TEXT | ISI 88. Wilson AM, McFarlane LC, Lipworth BJ. Effects of low and high doses of inhaled flunisolide and triamcinolone acetonide on basal and dynamic measures of adrenocortical activity in healthy volunteers. J Clin Endocrinol Metab. 1998;83:922-925. FREE FULL TEXT 89. Harrison LI, Purrington A, Leitch C, Machaek J, Van Den Burgt J, Vogel J. Beneficial effects of reduced particle size of CFC-free extra fine aerosol steroid on lung deposition, absorption, efficacy and safety [abstract]. Am J Respir Crit Care Med. 1997;155(suppl):A666. 90. Padfield PL, Teelucksingh S. Inhaled corticosteroids: the endocrinologist's view. Eur Respir Rev. 1993;3:494-500. 91. Sherman B, Weinbeger M, Chen-Walden H, Wendt H. Further studies of the effects of inhaled glucocorticoids on pituitary-adrenal function in healthy adults. J Allergy Clin Immunol. 1982;69:208-212. FULL TEXT | ISI | PUBMED 92. Wilson AM, Clark DJ, Devlin M, McFarlane LC, Lipworth BJ. Adrenocortical activity with repeated administration of once daily inhaled fluticasone propionate and budesonide in asthmatic adults. Eur J Clin Pharmacol. 1998;153:317-320. FULL TEXT 93. Brus RHB, Bodenheimer S. High-dose inhaled steroids in asthmatic children. Lancet. 1996;384:820-821. 94. Jennings BH, Anderson KE, Johannsson SA. Assessment of systemic effects of inhaled glucocorticoids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol. 1989;40:77-82. 95. Wilson AM, Lipworth BJ. A chronic dosing comparison of the systemic bioactivity with oral prednisolone and nebulised budesonide in adult asthmatic patients [abstract]. Br J Clin Pharmacol. 1998;45:185P. FULL TEXT 96. Agertoft L, Pedersen S. Bone mineral density on children with asthma receiving long term treatment with inhaled budesonide. Am J Respir Crit Care Med. 1998;157:178-183. FREE FULL TEXT 97. Allen DB, Bronsky EA, La Force CF, et al. Growth in asthmatic children treated with fluticasone propionate. J Paediatr. 1998;132:472-477. FULL TEXT | ISI | PUBMED 98. McCowan C, Neville RG, Thomas GE, et al. Effect of asthma and its treatment on growth: four year follow-up of cohort of children from general practice in Tayside, Scotland. BMJ. 1998;316:688-692. 99. Simons FER. A comparison of beclomethasone, sameterol and placebo in children with asthma. N Engl J Med. 1997;337:1659-1665. FREE FULL TEXT 100. Verberne AAPH, Frost C, DipStat MA, et al. One-year treatment with salmeterol compared to beclomethasone in children with asthma. Am J Crit Care Med. 1997;156:688-695. FREE FULL TEXT 101. Silverstein MD, Yunginger JW, Reed CE, et al. Attained adult height after childhood asthma: effect of glucocorticoid therapy. J Allergy Clin Immunol. 1997;99:466-474. FULL TEXT | ISI | PUBMED 102. Agertoft L, Pedersen S. Effects of long term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 1994;88:373-381. FULL TEXT | ISI | PUBMED 103. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics. 1993;92:64-77. FREE FULL TEXT 104. Merkus PJ, Van Essen-Zandvliet EE, van Houwelingen HC, Kerrebijn KF, Quanjer PH. Long-term effect of inhaled corticosteroids on growth rate in adolescents with asthma. Pediatrics. 1993;91:1121-1126. FREE FULL TEXT 105. Littlewood JM, Johnson AW, Edwards PA, Littlewood AE. Growth retardation in asthmatic children treated with inhaled beclomethasone dipropionate. Lancet. 1998;1:115-116. 106. Nassif E, Weinburger M, Sherman B, Brown K. Extrapulmonary effects of maintenance corticosteroid therapy with alternate day prednisolone and inhaled beclomethasone in children with chronic asthma. J Allergy Clin Immunol. 1987;80:518-529. FULL TEXT | ISI | PUBMED 107. Wolthers OD, Pedersen S. Short term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. Arch Dis Child. 1993;68:673-676. FREE FULL TEXT 108. Wolthers O, Pedersen S. Controlled study of linear growth in asthmatic children during treatment with inhaled glucocorticosteroids. Pediatrics. 1992;89:839-842. FREE FULL TEXT 109. Wolthers O, Pedersen S. Growth of asthmatic children during treatment with budesonide: a double-blind trial. BMJ. 1991;303:163-165. 110. MacKenzie CA, Wales JK. Growth in asthmatic children [letter]. BMJ. 1991;303:416. FREE FULL TEXT 111. Agertoft L, Pedersen S. Relationship between short term lower leg growth and long term statural growth in asthmatic children treated with budesonide [abstract]. Eur Respir J. 1996;9(suppl 23):294S. 112. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol. 1994;93:967-976. FULL TEXT | ISI | PUBMED 113. Balfour-Lynn L. Growth and childhood asthma. Arch Dis Child. 1986;61:1049-1055. FREE FULL TEXT 114. Wasnich R. Bone mass measurement: prediction of risk. Am J Med. 1993;95(suppl 5A):6S-10S. 115. Meeran K, Hattersley A, Burrin J, Shiner R, Ibbertson K. Oral and inhaled corticosteroids reduced bone formation as shown by plasma osteocalcin levels. Am Rev Respir Dis. 1995;151:333-336. 116. Grove A, McFarlane LC, Jackson CM, Lipworth BJ. Effects of short-term exposure to high dose inhaled corticosteroids on novel markers of bone metabolism. Eur J Clin Pharmacol. 1996;5:275-277. 117. Hodsman AB, Toogood JH, Jennings B, Fraher LJ, Baskerville JC. Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin. J Clin Endocrinol Metab. 1991;72:530-540. FREE FULL TEXT 118. Teelucksingh S, Padfield PL, Tibi L, Gough KJ, Holt PR. Inhaled corticosteroids, bone formation, and osteocalcin. Lancet. 1991;338:60-61. ISI | PUBMED 119. Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrel H, Tattersfield AE. Cross section investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma. Thorax. 1997;52:853-860. ABSTRACT 120. Lipworth BJ, Clark DJ. High dose inhaled steroids in asthmatic children [letter]. Lancet. 1996;348:820. ISI | PUBMED 121. Hanania NA, Chapman KR, Sturtridge WC, Szalii JP, Kesten S. Dose related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol. 1995;96:571-579. FULL TEXT | ISI | PUBMED 122. Kerstjens HA, Postma DS, van Dormaal JJ, et al. Effects of short-term and long-term treatment with inhaled corticosteroids of bone metabolism in patients with airways obstruction. Thorax. 1994;49:652-656. FREE FULL TEXT 123. Wolthers OD, Hansen M, Juul A, Nielson HA, Pedersen S. Knemometry, urine cortisol excretion, and measures of the insulin-like growth factor access and collagen turnover in children treated with inhaled glucocorticosteroids. Paediatr Res. 1997;41:44-50. ISI | PUBMED 124. Birkebaek NH, Esbjerg G, Andersen K, Wolthers O, Hassager C. Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate. Arch Dis Child. 1995;73:524-527. FREE FULL TEXT 125. Konig P, Hillman G, Gervantes C. Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate. J Paediatr. 1993;122:219-226. ISI | PUBMED 126. Sorva R, Turpeinen M, Jnutunen-Backman K, Karnonen S, Sorva A. Effect of inhaled budesonide on serum markers of bone metabolism in children with asthma. J Allergy Clin Immunol. 1992;9:808-815. 127. Luengo M, del Rio L, Pons F, Picado C. Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study. Eur Respir J. 1997;10:2110-2113. ABSTRACT 128. Martinati B, Bertoldo F, Gasperi E, Micelli S, Boner AL. Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma. Am J Respir Crit Care Med. 1996;153:232-236. ABSTRACT 129. Toogood JH, Baskerville J, Markov AE, et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol. 1995;96:157-166. FULL TEXT | ISI | PUBMED 130. Ip M, Lam K, Yam L, Kung A, Ng M. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest. 1994;105:1722-1727. FREE FULL TEXT 131. Baraldi E, Bollini MC, De Marchi A, Zacchello F. Effect of beclomethasone dipropionate on bone mineral content assessed by x-ray densitometry in asthmatic children: a longitudinal evaluation. Eur Respir J. 1994;7:710-714. ABSTRACT 132. Herrala J, Puolijoki H, Impivaara O, Liippo K, Tala E, Nieminen MM. Bone mineral density in asthmatic women on high dose inhaled beclomethasone dipropionate. Bone. 1994;15:621-623. PUBMED 133. Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM. Bone density in asthmatic patients taking high dose inhaled beclomethasone and intermittent systemic corticosteroids. Thorax. 1992;47:414-417. FREE FULL TEXT 134. Urban RC, Cotlier E. Corticosteroid induced cataracts. Surv Ophthalmol. 1986;31:102-110. FULL TEXT | ISI | PUBMED 135. Karim AKA, Thompson GM, Jacob TJC. Steroid aerosols and cataract formation [letter]. BMJ. 1989;299:918. FREE FULL TEXT 136. Fraunfelder FT, Mayer SM. Posterior subcapsular cataracts associated with nasal or inhaled corticosteroids. Am J Ophthalmol. 1990;109:489-490. ISI | PUBMED 137. Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen P. Steroid aerosols and cataract formation. BMJ. 1989;299:432-433. 138. Rooklin AR, Lampert SI, Jaeger EA, McGeady J, Mansmann HCJ. Posterior subcapsular cataracts in steroid requiring asthmatic children. J Allergy Clin Immunol. 1979;63:383-386. FULL TEXT | ISI | PUBMED 139. Shun-Shin GA, Brown NP, Bron AJ, Sparrow JM. Dynamic nature of posterior subcapsular cataract. Br J Ophthalmol. 1989;73:522-527. FREE FULL TEXT 140. Toogood JH, Markov AE, Baskerville J, Dyson C. Association of ocular cataracts with inhaled and oral steroid therapy during long term treatment of asthma. J Allergy Clin Immunol. 1993;91:571-579. FULL TEXT | ISI | PUBMED 141. Simons FER, Persaud MP, Gillespie CA, Chang M, Shuckett EP. Absence of posterior subcapsula cataracts in young patients treated with inhaled glucocorticoids. Lancet. 1993;342:776-778. FULL TEXT | ISI | PUBMED 142. Abuekteish F, Kirkpatrick JNP, Russell G. Posterior subcapsula cataract and inhaled corticosteroid therapy. Thorax. 1995;50:674-676. FREE FULL TEXT 143. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risks of cataracts. N Engl J Med. 1997;337:8-14. FREE FULL TEXT 144. Opatowsky I, Feldman RM, Gross R, Feldman ST. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology. 1995;102:177-179. ISI | PUBMED 145. Dreyer EB. Inhaled steroid use and glaucoma [letter]. N Engl J Med. 1993;329:1822. FREE FULL TEXT 146. Garb E, Le Lorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997;277:722-727. FREE FULL TEXT 147. Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Pupura and dermal thinning associated with high dose inhaled corticosteroids. BMJ. 1990;300:1548-1551. 148. Mak VHF, Melchor R, Spiro SG. Easy bruising is a side effect of inhaled corticosteroids. Eur Respir J. 1992;5:1068-1074. ABSTRACT 149. Roy A, Le Blanc C, Paquete L, et al. Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency in association with adrenal function. Eur Respir J. 1996;9:226-231. ABSTRACT

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 1999;159(9):1015-1016.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Effect of an Inhaled Corticosteroid on Glucose Control in Type 2 Diabetes
Faul et al.
Clin Med Res 2009;7:14-20.
ABSTRACT | FULL TEXT  

Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance
Awan et al.
Br J Ophthalmol 2009;93:708-713.
ABSTRACT | FULL TEXT  

Iatrogenic Cushing's Syndrome in HIV-Infected Patients Receiving Ritonavir and Inhaled Fluticasone: Description of 4 New Cases and Review of the Literature
Valin et al.
J Int Assoc Physicians AIDS Care (Chic Ill) 2009;8:113-121.
ABSTRACT  

Preemptive Use of High-Dose Fluticasone for Virus-Induced Wheezing in Young Children
Ducharme et al.
NEJM 2009;360:339-353.
ABSTRACT | FULL TEXT  

Prescribing trends in asthma: a longitudinal observational study
Turner et al.
Arch. Dis. Child. 2009;94:16-22.
ABSTRACT | FULL TEXT  

Update in the Understanding of Respiratory Limitations to Exercise Performance in Fit, Active Adults
Dempsey et al.
Chest 2008;134:613-622.
ABSTRACT | FULL TEXT  

Global strategy for asthma management and prevention: GINA executive summary
Bateman et al.
Eur Respir J 2008;31:143-178.
ABSTRACT | FULL TEXT  

Fracture Risk in Patients With Chronic Lung Diseases Treated With Bronchodilator Drugs and Inhaled and Oral Corticosteroids
Vestergaard et al.
Chest 2007;132:1599-1607.
ABSTRACT | FULL TEXT  

Adverse Effects of Inhaled Corticosteroids in Funded and Nonfunded Studies
Nieto et al.
Arch Intern Med 2007;167:2047-2053.
ABSTRACT | FULL TEXT  

Effect of choline chloride in allergen-induced mouse model of airway inflammation
Mehta et al.
Eur Respir J 2007;30:662-671.
ABSTRACT | FULL TEXT  

Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and the Risk of Hospitalization for Pneumonia
Ernst et al.
Am. J. Respir. Crit. Care Med. 2007;176:162-166.
ABSTRACT | FULL TEXT  

Exogenous Cushing Syndrome with Inhaled Fluticasone in a Child Receiving Lopinavir/Ritonavir
Bhumbra et al.
The Annals of Pharmacotherapy 2007;41:1306-1309.
ABSTRACT | FULL TEXT  

Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone
Paton et al.
Arch. Dis. Child. 2006;91:808-813.
ABSTRACT | FULL TEXT  

Side Effects With Inhaled Corticosteroids: The Physician's Perception
Irwin and Richardson
Chest 2006;130:41S-53S.
ABSTRACT | FULL TEXT  

Developing the Ideal Inhaled Corticosteroid
Cerasoli
Chest 2006;130:54S-64S.
ABSTRACT | FULL TEXT  

Osteoporosis in Men
Wright
J Am Acad Orthop Surg 2006;14:347-353.
ABSTRACT | FULL TEXT  

Low-dose inhaled and nasal corticosteroid use and the risk of cataracts
Ernst et al.
Eur Respir J 2006;27:1168-1174.
ABSTRACT | FULL TEXT  

Ciclesonide Reduces the Need for Oral Steroid Use in Adult Patients With Severe, Persistent Asthma
Bateman et al.
Chest 2006;129:1176-1187.
ABSTRACT | FULL TEXT  

Suppression of HPA axis in adults taking inhaled corticosteroids.
Greenfield and Samaras
Thorax 2006;61:272-273.
FULL TEXT  

Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease
van der Palen et al.
Thorax 2006;61:29-33.
ABSTRACT | FULL TEXT  

Allergic rhinitis.
Plaut and Valentine
NEJM 2005;353:1934-1944.
FULL TEXT  

Antiinflammatory action of glucocorticoids--new mechanisms for old drugs.
Rhen and Cidlowski
NEJM 2005;353:1711-1723.
FULL TEXT  

Long-Acting Bronchodilator or Leukotriene Modifier as Add-on Therapy to Inhaled Corticosteroids in Persistent Asthma?
Currie et al.
Chest 2005;128:2954-2962.
ABSTRACT | FULL TEXT  

Designer Inhaled Corticosteroids: Are They Any Safer?
Lipworth
Chest 2005;128:1081-1084.
FULL TEXT  

Ciclesonide, a Novel Inhaled Steroid, Does Not Affect Hypothalamic-Pituitary-Adrenal Axis Function in Patients With Moderate-to-Severe Persistent Asthma
Szefler et al.
Chest 2005;128:1104-1114.
ABSTRACT | FULL TEXT  

Inhaled Beclomethasone Dipropionate Acutely Stimulates Dose-Dependent Growth Hormone Secretion in Healthy Subjects
Bertoldo et al.
Chest 2005;128:902-905.
ABSTRACT | FULL TEXT  

Preclinical Profile of Ciclesonide, a Novel Corticosteroid for the Treatment of Asthma
Belvisi et al.
J. Pharmacol. Exp. Ther. 2005;314:568-574.
ABSTRACT | FULL TEXT  

Iatrogenic Cushing's Syndrome with Osteoporosis and Secondary Adrenal Failure in Human Immunodeficiency Virus-Infected Patients Receiving Inhaled Corticosteroids and Ritonavir-Boosted Protease Inhibitors: Six Cases
Samaras et al.
J. Clin. Endocrinol. Metab. 2005;90:4394-4398.
ABSTRACT | FULL TEXT  

Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease
Cooper and Tashkin
BMJ 2005;330:640-644.
FULL TEXT  

Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists
Currie et al.
QJM 2005;98:171-182.
ABSTRACT | FULL TEXT  

Growth Hormone Response to Growth Hormone-Releasing Hormone Is Reduced in Adult Asthmatic Patients Receiving Long-term Inhaled Corticosteroid Treatment
Malerba et al.
Chest 2005;127:515-521.
ABSTRACT | FULL TEXT  

Review: long term use of common medications for asthma reduces exacerbations in adults
Small
Evid. Based Nurs. 2005;8:14-14.
FULL TEXT  

The Risk of Nonvertebral Fracture Related to Inhaled Corticosteroid Exposure Among Adults With Chronic Respiratory Disease
Johannes et al.
Chest 2005;127:89-97.
ABSTRACT | FULL TEXT  

Loss of Bone Density with Inhaled Triamcinolone in Lung Health Study II
Scanlon et al.
Am. J. Respir. Crit. Care Med. 2004;170:1302-1309.
ABSTRACT | FULL TEXT  

Adrenal Suppression with Dry Powder Formulations of Fluticasone Propionate and Mometasone Furoate
Fardon et al.
Am. J. Respir. Crit. Care Med. 2004;170:960-966.
ABSTRACT | FULL TEXT  

Skin Manifestations of Inhaled Corticosteroids in COPD Patients: Results From Lung Health Study II
Tashkin et al.
Chest 2004;126:1123-1133.
ABSTRACT | FULL TEXT  

The use of inhaled corticosteroids during childhood: plus ca change...
Russell
Arch. Dis. Child. 2004;89:893-895.
FULL TEXT  

Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation
Hurst and Wedzicha
Postgrad. Med. J. 2004;80:497-505.
ABSTRACT | FULL TEXT  

Categorizing Asthma Severity: An Overview of National Guidelines
Colice
Clin Med Res 2004;2:155-163.
ABSTRACT | FULL TEXT  

Inhaled Corticosteroids and the Risk of Fractures in Children and Adolescents
Schlienger et al.
Pediatrics 2004;114:469-473.
ABSTRACT | FULL TEXT  

Leukotriene Modifier vs Inhaled Corticosteroid in Mild-to-Moderate Asthma: Clinical and Anti-inflammatory Effects
Perng et al.
Chest 2004;125:1693-1699.
ABSTRACT | FULL TEXT  

Recognizing and Treating Glucocorticoid-Induced Osteoporosis in Patients With Pulmonary Diseases
Gluck and Colice
Chest 2004;125:1859-1876.
ABSTRACT | FULL TEXT  

Adrenal Insufficiency from Inhaled Corticosteroids
White and Woodmansee
ANN INTERN MED 2004;140:W-27-W-27.
FULL TEXT  

Cushing's Syndrome Due to Interaction Between Inhaled Corticosteroids and Itraconazole
Bolland et al.
The Annals of Pharmacotherapy 2004;38:46-49.
ABSTRACT | FULL TEXT  

Risk-Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/Pharmacodynamic Perspective
Rohatagi et al.
J Clin Pharmacol 2004;44:37-47.
ABSTRACT | FULL TEXT  

Dose Equivalency Evaluation of Major Corticosteroids: Pharmacokinetics and Cell Trafficking and Cortisol Dynamics
Mager et al.
J Clin Pharmacol 2003;43:1216-1227.
ABSTRACT | FULL TEXT  

Aging Bone and Osteoporosis: Strategies for Preventing Fractures in the Elderly
Ettinger
Arch Intern Med 2003;163:2237-2246.
ABSTRACT | FULL TEXT  

Inhaled Fluticasone Propionate by Diskus in the Treatment of Asthma: A Comparison of the Efficacy of the Same Nominal Dose Given Either Once or Twice a Day
Purucker et al.
Chest 2003;124:1584-1593.
ABSTRACT | FULL TEXT  

A population based case-control study of cataract and inhaled corticosteroids
Smeeth et al.
Br J Ophthalmol 2003;87:1247-1251.
ABSTRACT | FULL TEXT  

Lack of Long-term Adverse Adrenal Effects From Inhaled Triamcinolone: Lung Health Study II
Eichenhorn et al.
Chest 2003;124:57-62.
ABSTRACT | FULL TEXT  

Adrenal crisis due to inhaled steroids is underestimated
Todd
Arch. Dis. Child. 2003;88:554-555.
FULL TEXT  

Stepping down inhaled corticosteroids in asthma: randomised controlled trial
Hawkins et al.
BMJ 2003;326:1115.
ABSTRACT | FULL TEXT  

Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma
Sim et al.
Eur Respir J 2003;21:633-636.
ABSTRACT | FULL TEXT  

Population Pharmacokinetics and Pharmacodynamics of Ciclesonide
Rohatagi et al.
J Clin Pharmacol 2003;43:365-378.
ABSTRACT | FULL TEXT  

Subconjunctival Nano- and Microparticles Sustain Retinal Delivery of Budesonide, a Corticosteroid Capable of Inhibiting VEGF Expression
Kompella et al.
IOVS 2003;44:1192-1201.
ABSTRACT | FULL TEXT  

Systemic activity of inhaled corticosteroid treatment in asthmatic children: corticotrophin releasing hormone test
Pescollderungg et al.
Thorax 2003;58:227-230.
ABSTRACT | FULL TEXT  

Safety Profile of Frequent Short Courses of Oral Glucocorticoids in Acute Pediatric Asthma: Impact on Bone Metabolism, Bone Density, and Adrenal Function
Ducharme et al.
Pediatrics 2003;111:376-383.
ABSTRACT | FULL TEXT  

Inhaled corticosteroids and adrenal insufficiency
Russell
Arch. Dis. Child. 2002;87:455-456.
ABSTRACT | FULL TEXT  

Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom
Todd et al.
Arch. Dis. Child. 2002;87:457-461.
ABSTRACT | FULL TEXT  

Management of Persistent Symptoms in Patients With Asthma
Lim
Mayo Clin Proc. 2002;77:1333-1339.
ABSTRACT  

Effect of Discontinuation of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease: The COPE Study
van der Valk et al.
Am. J. Respir. Crit. Care Med. 2002;166:1358-1363.
ABSTRACT | FULL TEXT  

Adrenal insufficiency after treatment with fluticasone
Lipworth et al.
BMJ 2002;325:836-836.
FULL TEXT  

Therapeutic Ratio of Hydrofluoroalkane and Chlorofluorocarbon Formulations of Fluticasone Propionate*
Fowler et al.
Chest 2002;122:618-623.
ABSTRACT | FULL TEXT  

Effects of Adding Either a Leukotriene Receptor Antagonist or Low-Dose Theophylline to a Low or Medium Dose of Inhaled Corticosteroid in Patients With Persistent Asthma*
Dempsey et al.
Chest 2002;122:151-159.
ABSTRACT | FULL TEXT  

Inhaled steroids in children: adrenal suppression and growth impairment
Carlsen and Gerritsen
Eur Respir J 2002;19:985-988.
FULL TEXT  

Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R)
Johnell et al.
Eur Respir J 2002;19:1058-1063.
ABSTRACT | FULL TEXT  

One-Year Trial on Safety and Normal Linear Growth with Flunisolide HFA in Children with Asthma
Gillman et al.
CLIN PEDIATR 2002;41:333-340.
ABSTRACT  

Systemic Effect Comparisons of Six Inhaled Corticosteroid Preparations
Martin et al.
Am. J. Respir. Crit. Care Med. 2002;165:1377-1383.
ABSTRACT | FULL TEXT  

Lesson of the week: Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate * Commentary: Exogenous glucocorticoids influence adrenal function, but assessment can be difficult
Drake et al.
BMJ 2002;324:1081-1083.
FULL TEXT  

Systemic effects of inhaled steroids
LIPWORTH et al.
Thorax 2001;56:980b-981.
FULL TEXT  

Symptomatic adrenal insufficiency during inhaled corticosteroid treatment
Patel et al.
Arch. Dis. Child. 2001;85:330-334.
ABSTRACT | FULL TEXT  

Effects of Inhaled Glucocorticoids on Bone Density in Premenopausal Women
Israel et al.
NEJM 2001;345:941-947.
ABSTRACT | FULL TEXT  

Mometason Furoate Levels
Lipworth and Affrime
Chest 2001;120:1034-1035.
FULL TEXT  

Alterations of Placental Vascular Function in Asthmatic Pregnancies
CLIFTON et al.
Am. J. Respir. Crit. Care Med. 2001;164:546-553.
ABSTRACT | FULL TEXT  

Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis Commentary: Dosage needs systematic and critical review
Holt et al.
BMJ 2001;323:253-253.
ABSTRACT | FULL TEXT  

THE PROBLEM OF DOSE-RESPONSE AND THERAPEUTIC RATIO OF INHALED STEROIDS
Lipworth et al.
Am. J. Respir. Crit. Care Med. 2001;163:1758-1759.
FULL TEXT  

Inhaled Triamcinolone and Chronic Obstructive Pulmonary Disease
Lipworth et al.
NEJM 2001;344:1553-1556.
FULL TEXT  

Fluticasone and Cortisol Measurements
Lipworth et al.
Chest 2001;119:984-985.
FULL TEXT  

Systemic effects of inhaled corticosteroids are milder in asthmatic patients than in normal subjects
FABBRI and MELARA
Thorax 2001;56:165-166.
FULL TEXT  

Montelukast and Churg-Strauss syndrome
LIPWORTH et al.
Thorax 2001;56:244-244.
FULL TEXT  

The ISOLDE trial
Lipworth et al.
BMJ 2000;321:1349-1349.
FULL TEXT  

New evidence of a link between inhaled corticosteroid use and osteoporosis
Myers
CMAJ 2000;163:1335-1335.
FULL TEXT  

Other articles noted
Evid. Based Nurs. 2000;3:106-112.
FULL TEXT  

Relative Effects of Exogenous Inhaled Corticosteroids on Diurnal Cortisol Secretion
Lipworth and de Mooij
Arch Intern Med 2000;160:2549-2550.
FULL TEXT  

Invasive Pulmonary Aspergillosis Associated with High-Dose Inhaled Fluticasone
Leav et al.
NEJM 2000;343:586-586.
FULL TEXT  

Low-Dose Inhaled Corticosteroids and the Prevention of Death from Asthma
Suissa et al.
NEJM 2000;343:332-336.
ABSTRACT | FULL TEXT  

Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis
SMYTH et al.
Thorax 2000;55:251-251.
FULL TEXT  

Adrenal Suppression, Evaluated by a Low Dose Adrenocorticotropin Test, and Growth in Asthmatic Children Treated with Inhaled Steroids
Kannisto et al.
J. Clin. Endocrinol. Metab. 2000;85:652-657.
ABSTRACT | FULL TEXT  

The use of inhaled corticosteroids in childhood asthma
DTB 1999;37:73-77.
ABSTRACT | FULL TEXT  

Drugs in the peri-operative period: 2 - Corticosteroids and therapy for diabetes mellitus
DTB 1999;37:68-70.
ABSTRACT | FULL TEXT